Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

13,059 total articles

Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity

Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity

Cardiff Oncology announced it will host a key opinion leader webinar on April 30, 2026, to discuss data from an investigator-initiated trial showing onvansertib's promising single-agent clinical activity in chronic myelomonocytic leukemia (CMML). The event features Dr. Mrinal Patnaik from Mayo Clinic and aims to highlight onvansertib's potential as…

U.S. Energy Corp. Signs Five-Year Helium Offtake Agreement with Investment-Grade Global Leader in Industrial Gases

U.S. Energy Corp. Signs Five-Year Helium Offtake Agreement with Investment-Grade Global Leader in Industrial Gases

U.S. Energy Corp. (NASDAQ: USEG) announced a five-year helium sales agreement with an investment-grade global industrial gas company for helium produced at its Big Sky Carbon Hub in Montana. The contract guarantees purchase of 100% of Phase 1 helium production at a fixed plant-gate price of $285 per thousand cubic feet with annual inflation adjustm…

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Intellia Therapeutics reported positive topline results from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z), a one-time in vivo CRISPR gene editing therapy targeting hereditary angioedema (HAE). The trial met its primary and all key secondary endpoints, showing an 87% reduction in attacks over six months versus placebo, with favo…

Verizon’s Transformation Actions Deliver Growth & Profitability in 1Q26; Company Raises Adjusted EPS Guidance

Verizon’s Transformation Actions Deliver Growth & Profitability in 1Q26; Company Raises Adjusted EPS Guidance

Verizon Communications Inc. reported solid financial and operating results for the first quarter of 2026, showcasing accelerating momentum in its strategic transformation efforts. The company achieved its highest quarterly adjusted EBITDA in history, positive postpaid phone net additions for the first time in over a decade, and raised its 2026 adju…

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

Oruka Therapeutics announced positive interim data from its EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis patients. The treatment achieved a 63.5% complete skin clearance rate (PASI 100) at 16 weeks with a safety profile similar to placebo and existing IL-23p19 inhibitors. Updated pharmacokinetic data support potentia…

Astec Announces Quarterly Dividend

Astec Announces Quarterly Dividend

Astec Industries, a manufacturer of specialized equipment for asphalt road building, aggregate processing, and concrete production, announced a quarterly dividend of $0.13 per share payable on May 29, 2026, to shareholders of record on May 13, 2026. The company operates in two main segments: Infrastructure Solutions and Materials Solutions, and als…

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics has completed enrollment in its PreciSION CF Phase 2a proof-of-concept trial, which evaluates its first-in-class NBD1 stabilizer, SION-719, added to the current cystic fibrosis standard of care Trikafta. Data from the trial is expected in summer 2026. This marks the first clinical study targeting the nucleotide binding domain 1 …

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026

Fulcrum Therapeutics announced positive clinical data from its Phase 1b PIONEER trial of pociredir for sickle cell disease, showing significant fetal hemoglobin induction and improvements in markers of hemolysis, anemia, and potential reduction in vaso-occlusive crises. The company plans to initiate a registration-enabling trial in the second half …

Lakeland Financial Reports Record First Quarter Performance; Loan Growth of 5% and Revenue Growth of 9% Contribute to 32% Increase in Net Income to $26.5 Million

Lakeland Financial Reports Record First Quarter Performance; Loan Growth of 5% and Revenue Growth of 9% Contribute to 32% Increase in Net Income to $26.5 Million

Lakeland Financial Corporation announced record first quarter 2026 net income of $26.5 million, a 32% increase from the prior year quarter, driven by 5% loan growth, strong net interest margin expansion, and 18% higher noninterest income. The bank experienced healthy organic loan growth, improved asset quality, and increased shareholder returns via…

Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors

Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors

Fulcrum Therapeutics appointed Dr. Josh Lehrer, a seasoned physician-scientist with extensive drug development experience in rare diseases, to its Board of Directors. Dr. Lehrer’s background includes leadership roles in developing therapies for sickle cell disease, notably contributing to the approval of Oxbryta. His addition is expected to bolster…

Amaze Signs LOI with Digital Innovations Holding Group, Inc. to Integrate IRMA Engine to Expand Creator and Fan Monetization Through Paid Influencer Program

Amaze Signs LOI with Digital Innovations Holding Group, Inc. to Integrate IRMA Engine to Expand Creator and Fan Monetization Through Paid Influencer Program

Amaze Holdings, Inc. (NYSE American: AMZE) announced an LOI to integrate Digital Innovations Holding Group's proprietary IRMA engine into its platform, aiming to create a new monetization layer for creators and fans via paid influencer programs. This integration will introduce the Amaze credit system to reward participation, promote affiliate commi…

Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

Relay Therapeutics announced promising clinical data for the combination of Zovegalisib, Atirmociclib, and aromatase inhibitors (AI) as a frontline triplet therapy for PIK3CA-mutated, HR+/HER2- metastatic breast cancer. The combination showed a 44% objective response rate (ORR) in heavily pre-treated patients, with favorable tolerance and manageabl…

Tower Semiconductor and Axiro Semiconductor Deliver High-Power, High-Efficiency SiGe ICs for Secure U.S. Defense Applications

Tower Semiconductor and Axiro Semiconductor Deliver High-Power, High-Efficiency SiGe ICs for Secure U.S. Defense Applications

Tower Semiconductor and Axiro Semiconductor announced the availability of high-performance radar beamforming integrated circuits (BFICs) built on Tower's Silicon Germanium (SiGe) technology. Fabricated in Tower's U.S. facilities and designed by Axiro, these BFICs are set to enhance performance in critical defense radar and satcom applications, meet…

Allied Gaming & Entertainment Announces Temporary No-Sale non-binding Commitment by Major Shareholder

Allied Gaming & Entertainment Announces Temporary No-Sale non-binding Commitment by Major Shareholder

Allied Gaming & Entertainment Inc. announced that its major shareholder, Primo, has made a non-binding commitment not to sell or transfer any of their shares until December 31, 2026, demonstrating support for the company's strategic direction and long-term growth. The commitment is non-binding and does not guarantee share retention. Allied Gaming i…